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1682-606X/Copyright ª 2015, TaiwanSummary The nature of hypertrophic scars and keloids can be unpredictable even to the
most experienced physicians. Predicting the susceptibility and severity of these disorders is
difficult. The availability of numerous treatment options which yield various results make
deciding on a course of treatment difficult. Further complicating the selection of treatment
options are the numerous industry-driven publications that seem biased and are supported
by marketing strategies for related products. Physicians often end up using a treatment modal-
ity that is not particularly objective or supported by a high level of evidence. Reviewing liter-
ature on this topic can be daunting. This study attempts to clarify the complex
fibroproliferative disorder of skin wound healing by briefly describing its pathophysiology, ca-
tegorizing patients into distinct groups based on their clinical behavior, and analyzing relevant
evidence for each treatment modality.
Copyright ª 2015, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The unpredictability of hypertrophic scars (HTSs) and ke-
loids can confuse the most experienced physicians. In 2014,of Burns, Plastic, Maxillofa-
yak Hospital and Associated
elhi 110 002, India.
(R.B. Ahuja).
02.001
Surgical Association. Published bythe International Advisory Panel on scar management
published a revision of the recommended practices pro-
moted by the first advisory panel in 2002,1,2 resulting in
new treatment algorithms. However, the numerous treat-
ment options available, combined with contrasting data,
continue to make deciding on a course of treatment diffi-
cult. Based on a review of existing data, this study attempts
to rationalize treatment options after observing the clinical
behavior of scars and examining the evidence associated
with various modalities, traditional as well as emerging,
used to treat excessive scarring.Elsevier Taiwan LLC. All rights reserved.
50 R.B. Ahuja et al.2. DiscussionFigure 1 A patient with extensive post-burn hypertrophic
scarring of trunk and neck with contracture.
Figure 2 A child with postsurgical keloid on sternum
following cardiac surgery.2.1. Pathophysiology and clinical behavior
Skin damage can result in scars when the wound healing
process is disrupted. This can be divided into three distinct
but overlapping phases: inflammation, proliferation, and
remodeling. A scaffold of the extracellular matrix (ECM) is
deposited by fibroblasts during the proliferative phase,
forming a structural framework that bridges the wound and
enables vascular ingrowth. The recruitment and prolifera-
tion of fibroblasts and the production of the ECM are
influenced by the following fibrogenic growth factors:
platelet-derived growth factor, insulin-like growth factor,
transforming growth factors b1 and b2 (TGF-b1 and TGF-
b2), and basic fibroblast growth factor.3 These fibrogenic
growth factors upregulate ECM production, increase the
rates of proliferation and/or migration of the fibroblasts,
and inhibit the production of proteases required for main-
taining the balance between production and degradation.
The ECM is degraded during the final maturation or
remodeling phase, and immature Type III collagen trans-
forms into mature Type I collagen. ECM degradation occurs
through the action of collagenases, proteoglycanases, and
other proteases released by mast cells, macrophages,
endothelial cells, and fibroblasts. Either excessive synthesis
of collagens, fibronectins, and proteoglycans by fibroblasts
caused by the absence of apoptotic signals or deficient
matrix degradation and remodeling may lead to keloid
formation and hypertrophic scarring.
In addition, recent evidence suggests that the severity of
inflammation or the type of immune response may predis-
pose to excess scar formation.4 Fibroblasts produce
increased amounts of collagen when adverse wound healing
factors are present, such as increased skin tension (except
ear lobes), delayed wound healing, and wound infection,
which prolong the inflammatory response. Experimental
evidence suggests that a prolonged inflammatory periodwith
immune cell infiltration increases fibroblast activity with
greater andmore sustained ECMdeposition, leading to keloid
formation.4 In addition, the type of immune response can
affect fibrogenesis. Development of a T helper, Th2
response, promotes fibrogenesis, whereas predominance of
a Th1 response attenuates tissue fibrosis.5 This may explain
why keloid scars spread beyond the margins of the original
wound, whereas hypertrophic scars, in which the immune
cell infiltrations decrease over time, remain within the
original wound margins and often regress with time.4
Hypertrophic scars (Fig. 1) and keloids (Fig. 2) that
develop following skin damage represent the ends of a
spectrum of healing by scarring (Fig. 3). However, patients
who develop keloids spontaneously and have a family his-
tory of keloids may be presumed to have a “keloid diath-
esis” (Fig. 4) a term introduced by Burd and Huang.6
Patients with a keloid diathesis may have a history of
multiple scarring, and the high recurrence rate makes such
scarring appear as a benign fibroproliferative tumor.
Structurally and biochemically, hypertrophic scars have
more Type III collagen compared with keloidal scars, which
contain a higher Type I:Type III collagen ratio. Hypertrophic
scars have fine collagen fibers with more a-smooth muscleactin-containing myofibroblasts, whereas keloidal scars
have coarse collagen fibers with fewer a-smooth muscle
actin-containing myofibroblasts.6
Skin pigmentation is one of the major risk factors for the
development of keloids. Keloids are observed in people of
all races, except albinos. People with dark skin are more
susceptible to keloid formation, with a reported incidence
rate of 6e16% in African populations.7 The fact that this
condition never occurs in albinos, or on the palms or soles,
is testimony to the fact that keloids are associated with
increased skin pigmentation. There is increased sensitivity
to melanocyte-stimulating hormone (MSH) which leads to a
Figure 3 A schematic representation of authors’ understanding of the spectrum of fibroproliferative disorders of wound healing.
“Keloid diathesis” is viewed as a benign fibroproliferative tumor and hence depicted in the same spectrum, yet detached from the
mainstream healing process.
Figure 4 A patient with extensive keloids on the chest and
breasts representing “keloid diathesis”.
Evidence appraisal for treatment of hypertrophic scars 5120-fold increase in the likelihood of keloid formation.
Furthermore, keloid forming tendency is also increased in
puberty and pregnancy (because of increased MSH activity).
Taylor et al8 reported that a-MSH, which is produced by
melanocytes, could increase TGF-b secretion and inhibit
interferon (IFN)-a production by activating T cells, thus
stimulating the multiplication of fibroblasts.The clinical management of scarring is complicated by a
lack of precise characterization of each scar category,
interchangeable use of the terms hypertrophic scars and
keloids, a lack of appreciating keloid diathesis as an inde-
pendent entity, and the availability of few therapeutic in-
terventions that are supported by well-designed
prospective studies involving adequate control groups.
Moreover, there is no animal model for studying the bio-
logical behavior of keloids in humans, thus our under-
standing of this subject is hampered.
2.2. Critical appraisal of current therapies for
hypertrophic scars and keloids
2.2.1. Pressure therapy
Pressure therapy has been used for both prophylaxis and
treatment of hypertrophic scars and keloids since the
1970s. Although the underlying mechanism of action is
poorly understood, possible mechanisms of action are
decreased collagen synthesis by limiting oxygen supply and
increased apoptosis of fibroblasts.9 Recommendations for
the amount of pressure and the duration of therapy are
based on empirical observations, and support providing a
continuous pressure of 25e40 mmHg administered for at
least 23 hours per day for >6 months, while the scar is still
active. A recent study observed that 20e25 mmHg was
more effective than 10e15 mmHg in treating hypertrophic
scars.10 However, according to a meta-analysis in 2009, no
change in global scar scores was observed by pressure
therapy, and only a small (but statistically significant)
52 R.B. Ahuja et al.improvement was observed in scar height.11 Pressure
therapy is limited by the ability to adequately fit the
garment to the wounded area and by reduced compliance
caused by side effects such as maceration and odor in hot
and humid climates. Despite these limitations, some au-
thors have reported the effectiveness of pressure therapy
in pediatric age groups.12 In addition, postoperative pres-
sure applied with pressure earrings reportedly reduces
recurrence rates markedly after surgical repair of earlobe
keloids.13
Currently, the recommended clinical use of pressure
garments is restricted to deep dermal wounds that have
healed spontaneously over weeks, grafted wounds sur-
rounded by a deep dermal wound that have been allowed to
heal spontaneously over weeks, hypertrophic wounds in
children and young adults, wounds in people with dark skin,
and wounds in anatomical locations where compression can
be applied.14 Ogawa (2010)15 recommended pressure ther-
apy alone for contracture-free hypertrophic scars that
would otherwise improve by physiologic scar maturation. A
large multicentric trial is necessary to determine optimal
approach, but the authors’ personal experience is in line
with the aforementioned recommendations. Currently, this
is the only option available for managing widespread
postburn hypertrophic scarring (Fig. 1).
2.2.2. Silicone-based products
The mechanism of action of silicone-based products on
scar tissue is unknown. Some researchers have suggested
that silicone may penetrate the skin, but others have dis-
missed this idea.16 Normalization of transepidermal water
loss was suggested as the likely underlying mechanism.17 A
Cochrane review recently concluded that most related
studies have been of poor quality; therefore, the efficacy of
silicone gel sheets remains unclear.18 Nevertheless, the
current guidelines on scar management regard silicone gel
sheeting as the first-line therapy for linear hypertrophic or
widespread burn hypertrophic scars and minor keloids.1 A
study by Nast et al19 recommended that silicone sheets be
applied for 12e24 hours per day over a period of
12e24 weeks, beginning 2 weeks after the wounding. Sili-
con gels are equally or more effective than silicone gel
sheets, and they are most commonly used with pressure
therapy.
2.2.3. Intralesional triamcinolone injection
Intralesional triamcinolone acetonide (TAC) is regarded as
the gold standard in the management of less extensive
hypertrophic scars and keloids and has been in use since the
1960s. Synthetic corticosteroids decrease the production of
inflammatory cytokines, chemokines, and lysosomal en-
zymes, and inhibit fibroblast proliferation.20 Furthermore,
scars treated with TAC exhibit decreased levels of the
proteinase inhibitors a-2-macroglobulin and a-2-antitrypsin
in the scar, leading to decreased collagenase (matrix met-
alloproteinase 1) degradation.21
Generally, 3e4 TAC injections (40 mg/ml) delivered via a
25-26 g needle or dermojet, every 3e4 weeks are suffi-
cient, although occasionally the course may continue for 6
months or more. Most studies on intralesional injections for
scarring can be criticized for one or more technical lapses
of the trial, such as not defining the scar age forrecruitment, not specifying the drug dose per unit of the
scar, defining the end point of each injection inaccurately,
or applying an inappropriate frequency of injections.22 In
addition, none of these studies has segregated scars
accompanied by a keloid diathesis, which pathophysiolog-
ically behave quite differently.6 Ahuja and Chatterjee22
attempted to approach related trials more objectively by
clearly defining the parameters for scar recruitment and
injection. They established a relationship between a drug
volume of 1.5 ml and a scar area of approximately 6 cm2 to
ensure complete blanching of the lesion at the endpoint of
injection without exceeding the safe dose for TAC. All scars
received 0.7e0.9 ml of the drug (TAC) at the initial stages
and 1e1.5 ml as they softened. However, because of a lack
of strong supporting evidence, Ahuja and Chatterjee rec-
ommended that the proposed 3-week injection schedule,
based on previous studies, should be reviewed to determine
a more frequent regimen. A Chinese study proposed the use
of a combination of 5-fluorouracil (5-FU) (50 mg/ml) and
triamcinolone (40 mg/ml) at weekly intervals in a pro-
spective trial.23
Response rates with intralesional steroids are reported
from 50% to 100% and recurrence rates from 9% to 50%.24
Combining TAC with 5-FU, pulsed dye laser (PDL), and
cryotherapy has been reported to be more beneficial than
TAC monotherapy, although few randomized controlled
trials (RCTs) have tested these modalities.15 For older le-
sions, TAC was combined with cryotherapy for greater and
more marked response rates and is currently the most
widely used modality in Europe.12 The success rate of this
approach reportedly increased because larger volumes of
TAC could be injected into the scar following softening
caused by cryotherapy.12 A study in 2006 concluded that
TAC injections alone were effective in reducing the volume
of lesions in most patients.25 Our experience validates this
report for hypertrophic scars and keloids (without a
diathesis).22
Injecting the steroid sufficiently below the epidermis is
crucial, or epidermal atrophy and extravasation in the
surrounding tissue may ensue. Other adverse effects
include telengiectasias, hypopigmentation, and pain at the
injection site.12 Currently, intralesional TAC is the therapy
of choice for small hypertrophic scars and recent-onset
keloids.2
2.2.4. Cryotherapy
Cryotherapy with liquid nitrogen has been used either as a
monotherapy or in combination with intralesional TAC for
treating keloids.15 Traditional cryotherapy combined with
intralesional TAC augments therapeutic efficacy. In an RCT,
Layton et al26 reported that early vascular lesions respon-
ded significantly more effectively to cryosurgery than late
lesions. Cryotherapy acts by inducing vascular damage,
leading to anoxia and ultimately tissue necrosis. Approxi-
mately three to six sessions are typically necessary (at 3e4-
week intervals) to generate appropriate responses and
postintervention healing. Commonly occurring side effects
include permanent hypo- and hyperpigmentation, blis-
tering, and postoperative pain.27
Compared with contact probes, intralesional cryoprobes
(administered by needling) have an increased efficacy with
a shorter re-epithelialization period. Cryotherapy is
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conventional treatment techniques. Har-Shai et al28 re-
ported a scar volume reduction of 70% for earlobe keloids
and 60% for keloids on the upper back, shoulders, and chest
following a single cryotherapy session. The only adverse
event noted by the authors was minimal hypopigmentation,
with a nonresponse rate of <3%.
2.2.5. Intralesional verapamil
In 1990, Lee and Ping29 demonstrated that calcium channel
blockers such as verapamil cause decreased extracellular
matrix production in scars. Another study by Boggio et al30
in 2011 demonstrated that verapamil depolymerizes actin
filaments to modify fibroblast morphology with a conse-
quent increase in procollagenase secretions. Other studies
have reported using intralesional verapamil for treating
burn scars and earlobe keloids. Margaret Shanthi et al31
were first to report that intralesional verapamil may be as
effective as TAC in treating hypertrophic scars and keloids.
An RCT conducted by Ahuja and Chatterjee22 concluded
that verapamil is almost as effective as TAC and offers
several therapeutic possibilities in addition, such as use
with triamcinolone in an alternating fashion or even
simultaneously in the treatment of larger or multiple scars.
They also recommended administering a dose of 1.5 ml of
verapamil (2.5 mg/ml) per 6 cm2 area of lesion, injected
every 3e4 weeks. Lesions generally require seven to eight
sessions of injections (2e3 sessions more than when using
triamcinolone injections) and show no major adverse
reactions.22
2.2.6. Lasers
A vascular-specific pulse dye laser (PDL) to treat hyper-
trophic scars is rarely used in the clinical environment;
however, it has become the standard of care in some major
burns centers.32 Lasers have been used either to prevent or
treat hypertrophic scars by selective destruction of scar
microvasculature through targeted photothermolysis.
Other mechanisms for achieving clinical efficacy include
decreased cellular activity resulting from anoxia or colla-
genolysis by laser-stimulated cytokine release.
Historically, the 585 nm PDL has been shown to effec-
tively improve the pliability and texture of hypertrophic
scars, as well as reduce the erythema and associated
symptoms of pain and pruritus33; however, some recent
studies do not agree with these findings.32 A study by Alster
and Nanni33 reported that an average of two to three
treatment sessions with an energy range of 4.5e6.5 J/cm2
was required to reduce the scar surface area, and only one
to two sessions were necessary to alleviate the symptoms.
Treatment intervals of approximately six weeks were rec-
ommended. Optimal results were obtained when the lasers
were applied early. Following on from this study, the
595 nm PDL has recently been found to have even greater
efficacy34; however, more RCTs are required to test its
efficacy and indications. The side effects are generally
mild and predominantly include purpura, typically persist-
ing for 7e14 days. Depending on the energy density
employed, vesicles and crusts may occur.12 In another
study the 1064 nm Nd:YAG laser has recently shown
promise. The underlying mechanisms of action may be
similar to PDL, but the Nd:YAG reaches greater depths.Nevertheless, its ability to treat thick keloids may be
limited because its efficacy decreases with the thickness of
the scar.35
Ablative or nonablative fractional and microfractional
laser resurfacing procedures for correcting the abnormal
texture and pliability of a burn scar have been used and are
a focus of ongoing research.36 Similarly, intense pulsed light
therapy has also been investigated in alleviating burn scar
dyschromia and chronic folliculitis.37 However, based on
the recently published German guidelines for treating
excessive scarring, PDL is primarily recommended for
reducing erythema in highly vascularized red scars, and for
treating severe pruritus. According to these guidelines,
treatment with conventional CO2 or Erbium-YAG lasers may
be recommended for the ablation of inactive hypertrophic
scars.19 At a minimum, laser therapies can be combined
with other commonplace treatments in managing burns
scars.
2.2.7. Intralesional antimitotic drugs
Antineoplastic agents, such as 5-FU, bleomycin, and mito-
mycin C (MC), are used in the management of hypertrophic
scars and keloids. In particular, 5-FU has recently shown
some efficacy in the treatment of keloids and HTS.38 It acts
by inhibiting DNA synthesis, thereby increasing fibroblast
apoptosis. Haurani et al39 combined 5-FU with a surgical
excision of keloids, which failed to respond to intralesional
TAC alone; only 19% of them recurred after 1 year of follow-
up. Most studies have used the high-dose version of 5-FU
therapy (40e50 mg/ml) to destroy the keloid. A low-dose
therapy that involves using 1.4e3.5 mg/ml of 5-FU has
been shown to produce excellent results.40 In addition,
there is enough evidence to support the use of a combi-
nation of TAC (40 mg/ml) and 5-FU (50 mg/ml) in a 1:9
ratio.41
Bleomycin sulfate, another antineoplastic agent, was
found to directly inhibit collagen synthesis through
decreased stimulation by TGF-b1.42 Most studies have
demonstrated notable improvements in scar height and
pliability, as well as reduction in erythema, pruritus, and
pain after three to five injections (by using multiple needle
puncture or jet injections) of bleomycin (1.5 IU/ml) with a
maximum of 2 ml/cm2 of skin.43 However, this option is
more expensive compared with steroids and 5-FU. Appar-
ently, bleomycin is a promising alternative to 5-FU; how-
ever, cautious handling is necessary because of its toxicity
and additional relevant studies are warranted.
Mitomycin C is an antineoplastic agent that inhibits DNA
synthesis. Most studies on MC have been small and uncon-
trolled, with a high degree of methodological variability.
Few data on hypertrophic scarring are available, and most
data on keloids are based on clinical experience in post-
operative management.36 Additional studies are necessary
for establishing this therapy.
Based on the aforementioned data, we recommend
using antitumor drugs only for keloid diathesis and keloidal
scars which are resistant to other measures. The side ef-
fects may include pain, hyperpigmentation, skin irritation,
and ulceration. Contraindications are anemia, leukopenia,
thrombocytopenia, pregnancy, bone marrow depression,
and infection. No systemic side effects have been
reported.36,38e43
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Superficial X-rays, electron beams, and low- or high-dose
brachytherapy have been used as an adjunct to surgical
removal of keloids, with favorable results in reduced
recurrence.44,45 Radiation mediates its effects on keloids
through inhibition of neovascular buds and proliferating fi-
broblasts, resulting in decreased collagen production. A
dose of 12 Gy divided into six to 10 fractions, applied daily
or every second day starting 24 hours after surgery, is
currently recommended.19 The side effects include hypo-
and hyperpigmentation, erythema, telangiectasia, and at-
rophy.46 As radiation entails risks regarding carcinogenesis,
particularly in areas such as the breasts or thyroid, it should
be used with caution, even if the risk is low.46 Even after
radiotherapy and surgery, a recurrence rate of 9e72% has
been reported, which generally depends on the total dose
of radiation and duration of follow-up.44 We suggest that
radiation therapy should be reserved for keloid diathesis
alone because other modalities can adequately treat HTS
and keloidal scars.
2.2.9. Immunomodulators
Imiquimod cream (5%) acts topically by modifying the im-
mune response, and works by stimulating IFNs that increase
collagen breakdown. Additionally, imiquimod alters the
expression of apoptosis-associated genes, and is reportedly
effective in preventing recurrence of earlobe keloid after
excision.47 However, a high recurrence rate reported in
another study and contrasting data make this option
questionable.5,47,48
IFN-a2b therapy can decrease the synthesis of Type I
and Type III collagen and it directly antagonizes the effects
of TGF-b and histamine.49 One study showed that the sys-
temic administration of IFN-a2b resulted in improved out-
comes in seven out of nine patients.50 However,
intralesional IFN injections have not been shown to have
any effect.51 In addition, adverse effects are common with
IFN treatment, including flu-like symptoms and pain on
injection.49
In 2009, Ferguson et al52 summarized the results of three
double-blind, placebo-controlled trials with intradermal
avotermin (recombinant TGF-b3). However, in 2011, after
avotermin failed to hit its primary and secondary endpoints
in a Phase III trial, Renovo, the company manufacturing
avotermin, concluded that the efficacy of avotermin may
be insufficient in demonstrating significant benefits.53 We
currently do not recommend the use of IFN or imiquimod;
however, IFN may be a promising option in future for
treating resistant keloids or extensive hypertrophic scars.
2.2.10. Onion extracts (Extractum cepae)
Extractum cepae has flavonoids (quercetin and kaempferol)
that may play a role in scar reduction by inhibiting fibro-
blast proliferation. It is hypothesized that these inhibitory
effects may be mediated through the inhibition of TGF-b1
and TGF-b2 by quercetin. Considerable industry-driven
data have yielded contrasting results, thus diminishing the
credibility of using such drugs. However, recent studies
have shown that scar creams containing onion extracts can
significantly improve scar height and associated symptoms
compared with a placebo. They also appear to be effective
in preventing unaesthetic scars in patients who undergolaser removal of tattoos. In addition, such creams are
effective when used in combination with intralesional
TAC.54
2.2.11. Botulinum toxin A
Botulinum toxin A (BTA) immobilizes local muscles to
reduce skin tension. Reduction of the tensile force during
the course of cicatrization in addition to effective regula-
tion of the balance between fibroblast proliferation and
cellular apoptosis may represent a novel therapeutic option
for the aesthetic improvement of postsurgical scars. Gass-
ner et al55 demonstrated that administering BTA injections
into the musculature adjacent to the wound (15 U and 2 cm
incision length) within 24 hours after wound closure resul-
ted in enhanced wound healing and less noticeable scars
compared with a placebo. Other studies have advocated
injecting BTA 4e7 days prior to surgery.12 Recently, intra-
lesional BTA was proposed for treating established keloids
in a prospective, uncontrolled study.56 BTA was injected
at 3-month intervals for 9 months at a concentration of
35 U/ml. The total dose ranged from 70 to 140 units per
session. At the 1-year follow-up, eight out of 12 patients
showed favorable-to-excellent results with no failures.
Within the follow-up period of 1 year, no signs of recur-
rence were observed in any of the patients. However,
another objective evaluation of BTA-treated keloids that
entails using optical profilometry revealed no changes in
scarring compared with the baseline characteristics.57
Additional in-depth studies are required before this
comparatively expensive therapy can be suggested for the
treatment of excessive scarring.36
3. Conclusions
Hypertrophic scars, keloids, and scars of a keloid diathesis
behave distinctly. A keloid diathesis should be considered a
different entity because it behaves in the manner of a
benign fibroproliferative tumor of wound healing. Although
the treatment strategies are common for all scars, we
believe that antimitotic therapy (e.g., 5-FU) or radio-
therapy should be reserved for a keloid diathesis; however,
5-FU may be rarely necessary for treating resistant keloidal
scars. Almost all hypertrophic scars and keloids can be
managed using TAC or verapamil injections, and softening
by cryotherapy can hasten response in long-standing scars.
Compression garments and silicone gel or sheets are
invariably used as adjuncts, although the supporting evi-
dence is not strong. Furthermore, pressure therapy and
silicone sheets are the only modalities available in pre-
venting and treating extensive postburn hypertrophic
scarring. Emerging therapies, such as BTA or IFN, have not
been subjected to large-scale RCTs, and avotermin has
failed to demonstrate adequate response in Phase III trials.
Creams with a combination of onion extracts and heparin
continue to be used extensively, although supporting evi-
dence has emerged only recently and is still weak. Lasers
are primarily used to diminish the hyperemic response or
treat scar folliculitis. An informed approach is necessary to
effectively manage scar hypertrophy. Preventing hyper-
trophy by following the surgical principles of wound healing
is critical.
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